GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surmodics Inc (NAS:SRDX) » Definitions » Cash, Cash Equivalents, Marketable Securities

SRDX (Surmodics) Cash, Cash Equivalents, Marketable Securities : $31.1 Mil (As of Mar. 2025)


View and export this data going back to 1998. Start your Free Trial

What is Surmodics Cash, Cash Equivalents, Marketable Securities?

Surmodics's quarterly cash, cash equivalents, marketable securities declined from Sep. 2024 ($40.11 Mil) to Dec. 2024 ($30.15 Mil) but then increased from Dec. 2024 ($30.15 Mil) to Mar. 2025 ($31.15 Mil).

Surmodics's annual cash, cash equivalents, marketable securities increased from Sep. 2022 ($19.00 Mil) to Sep. 2023 ($45.35 Mil) but then declined from Sep. 2023 ($45.35 Mil) to Sep. 2024 ($40.11 Mil).


Surmodics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Surmodics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surmodics Cash, Cash Equivalents, Marketable Securities Chart

Surmodics Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.10 38.87 19.00 45.35 40.11

Surmodics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.94 38.18 40.11 30.15 31.15

Surmodics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Surmodics  (NAS:SRDX) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Surmodics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Surmodics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Surmodics Business Description

Industry
Traded in Other Exchanges
N/A
Address
9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. Geographically, the company derives key revenue from its domestic market.
Executives
Timothy J. Arens officer: General Manager - IVD 9924 WEST 74TH STREET, EDEN PRAIRIE X1 55344
Jose H Bedoya director
David Dantzker other: See Explanation of Responses 80 CUTTERMILL ROAD STE 311, GREAT NECK NY 11021
Kalich Ronald B Sr director
Gary R Maharaj director, officer: President & CEO 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Joseph J. Stich officer: VP, Corp Dev & Strat Planning 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Charles W Olson officer: General Manager
John D. Manders officer: Corporate Controller 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gordon S. Weber officer: Sr. VP of Legal, GC and Sec. 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Nusrath Sultana officer: VP, Clinical Affairs 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Lisa Wipperman Heine director 1244 76TH STREET WEST, INVER GROVE HEIGHTS MN 55077
Teri Woodwick Sides officer: Senior VP and CMO 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gregg S Sutton officer: VP of Research and Development 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Susan E Knight director 9154 BRECKENRIDGE LANE, EDEN PRAIRIE MN 55437
Bryan K Phillips officer: Dep. Gen. Counsel & Corp. Sec. 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344